Companies › CADL

CANDEL THERAPEUTICS INC (CADL)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001841387 · EDGAR filings · Updated 2026-07-27

CANDEL THERAPEUTICS INC (CADL) has reported institutional ownership of 59.3%, with 114 institutional managers holding positions valued at $212.9M per the latest 13F reporting period. SEC filings include an active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings.

Filings this week (1)

• 2026-07-27 — SCHEDULE 13G filed

Every filing links to the official SEC document. Real-time filing alerts for this company are available inside the app.

Latest updates

• 2026-07-08 — Insider transaction reported (Form 4)
• 2026-07-08 — Initial insider ownership filed (Form 3)
• 2026-07-01 — Insider transaction reported (Form 4)
• 2026-07-01 — Insider transaction reported (Form 4)
• 2026-07-01 — Insider transaction reported (Form 4)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, CANDEL THERAPEUTICS INC has 114 institutional holders and institutional ownership of 59.3%.

Insider activity

Insiders reported 14 transactions (1 buys, 2 sells) across 10 reporting insiders, with a net reported value of $2.99M.

Data flags from SEC filings

Related companies

C4 THERAPEUTICS INC (CCCC) · CLIMB BIO INC (CLYM) · ALTIMMUNE INC (ALT) · FOGHORN THERAPEUTICS INC (FHTX) · NAUTILUS BIOTECHNOLOGY INC (NAUT) · KEROS THERAPEUTICS INC (KROS)